Now approved
in the U.S.

EMPAVELI (pegcetacoplan) injection 1080mg / 20mL solution

Please see full Prescribing Information, including Boxed WARNING and Medication Guide.

US-CORP-2100013, v1.0, 05/14

Fearlessly Advancing


the first potential treatment
in geographic atrophy

Learn More
Leaders in Complement


at the forefront of targeted
C3 therapies

Learn More

With courageous science, creativity, and compassion,
we are committed to delivering therapies for people with
complement-driven diseases.

About Us
Folded page of a newspaper

Latest news

September 9, 2021

Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022

August 9, 2021

Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results

July 29, 2021

Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results

A man with a baby in a baby carrier

At the heart of our company is the belief that exceptional science and compassion are not mutually exclusive.

Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

Our groundbreaking science

targeting C3 offers the potential to provide comprehensive control of complement, a part of the immune system

Our Science
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

We aim to transform

treatment across a broad range of debilitating diseases driven by complement